![Craig Millian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Craig Millian
Amministratore Delegato presso
HLS THERAPEUTICS INC.
Patrimonio netto: 43 500 $ in data 30/06/2026
Profilo
Craig Millian is currently Chief Executive Officer & Director at HLS Therapeutics, Inc. since 2023.
Former roles include Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. from 2021 to 2023, Senior Vice President-Neurology & Immunology at EMD Serono, Inc. from 2016 to 2018, Vice President-Commercial at Vertex Pharmaceuticals, Inc., and a position at EMD Serono, Inc. from 2012 to 2018.
Education includes an undergraduate degree from the University of Pennsylvania and an MBA from New York University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 26/06/2026 | 14.500 ( 0,05% ) | 43 500 $ | 30/06/2026 |
Posizioni attive di Craig Millian
| Società | Posizione | Inizio |
|---|---|---|
| HLS THERAPEUTICS INC. | Amministratore Delegato | 01/05/2023 |
Precedenti posizioni note di Craig Millian
| Società | Posizione | Fine |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Direttore operativo | 14/04/2023 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01/12/2018 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Formazione di Craig Millian
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
22
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
HLS Therapeutics, Inc.
 HLS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
